Compare ECF & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | PYXS |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.1M | 243.5M |
| IPO Year | N/A | 2021 |
| Metric | ECF | PYXS |
|---|---|---|
| Price | $11.47 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 57.7K | ★ 633.1K |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | ★ $2,820,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.61 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.02 | $0.83 |
| 52 Week High | $8.91 | $5.55 |
| Indicator | ECF | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 40.63 | 22.73 |
| Support Level | $11.31 | $4.10 |
| Resistance Level | $12.05 | $4.58 |
| Average True Range (ATR) | 0.20 | 0.42 |
| MACD | -0.04 | -0.27 |
| Stochastic Oscillator | 20.27 | 5.48 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.